Aphios®, a Massachusetts-based biotech company that has developed cannabis-based pain relief drugs without the help of opioids for treating central and peripheral nervous system disorders like cancer pain or Multiple Sclerosis (MS), has raised over $93K in capital from more than 75 investors through an equity crowdfunding campaign on Wefunder. The green-biotech company that utilizes nanoencapsulated technology in its delivery methods has a valuation of $70 million and a starting investment of $250.
Founded by Dr. Trevor P. Castor, Aphios® Pharma is focused on developing, marketing, and delivering cannabis-based medicines to treat devastating disorders of the central and peripheral nervous systems. Their goal is to make FDA-approved prescription drugs that can alleviate pain for those living with chronic illnesses such as opioid use disorder or chemotherapy neuropathy which medical marijuana only treats sporadically and acutely.
“My AHA moment and inspiration for coming up with my company and products started with my childhood in Trinidad where I observed my maternal grandmother’s use of herbal medicines that fueled my interest in the natural healing aspects of medicinal plants such as Cannabis,” said Dr. Castor. “Aphios® uses nanotechnology as a delivery method for therapeutics that provide a more prolonged and sustained release. The delivery of natural products such as cannabinoids from Cannabis to a therapeutic target is usually hampered by poor oral bioavailability due to hydrophobicity and first-pass metabolism. We overcome these limitations by nanoencapsulating them in biodegradable, hydrophobic polymer nanospheres.” Dr. Castor adds.
The FDA-approved use of more than 60% of natural products is a positive sign for the future. Still, it shows how many pharmaceutical companies have downsized or eliminated their research using organic solvents. These toxins can be challenging to remove from bioactive compounds, which may mask any activity in tests conducted on them. Their technology platforms based on SuperFluids™ [SFS], proprietary and patented by Aphios®, enhance the drug discovery process and provide a much higher proportion of “hits” in drug screening programs showing an advantage over conventional extraction and purification screening.
“My passion is to improve health and wellness – physical, mental, and spiritual health – using the healing power of nature – sunshine, medicinal plants, and marine organisms – in an environmentally sustainable manner while curtailing climate change,” states Dr. Castor.
Aphios® Pharma’s equity crowdfunding campaign on Wefunder will close on 31st July 2022. For more information, visit their Wefunder page.
About Aphios® Pharma:
Aphios® Pharma is dedicated to the discovery, delivery, development, and commercialization of cannabis-based drugs for CNS and other debilitating disorders. They are developing FDA-approved, cannabis-based drugs for treating highly unmet central and peripheral nervous system disorders such as opioid addiction and chemotherapy-induced peripheral neuropathic pain that are only acutely addressed by medical marijuana. Aphios® Pharma utilizes patented and proprietary nanotechnologies to improve oral bioavailability of disease-specific cannabinoids and control their release for the treatment of chronic diseases, converting natural drugs that are anecdotally used to treat acute conditions into well-defined and characterized drugs for chronic conditions.in an environmentally sustainable manner while curtailing climate change,” states Dr. Trevor.
Aphios® Pharma’s equity crowdfunding campaign on Wefunder will close on 31st July. For more information, visit their Wefunder page.
Media Contact
Company Name: Aphios Pharma LLC
Contact Person: Dr. Trevor P. Castor
Email: Send Email
Phone: (001) (781) 932-6933
Address:3-E Gill Street, New Boston Park
City: Woburn
State: MA 01801
Country: United States
Website: https://aphios.com/
